SCHEMBL94476

SCHEMBL94476

C[N+](C)(C)CC(CC(=O)O)OC(=O)C(O)C(O)C(=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
CYP1A2 P05177 4/20 0.50
HRH1 P35367 1/20 0.50
MAPT P10636 5/20 0.49
MAPK1 P28482 4/20 0.49
GMNN O75496 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
TP53 P04637 3/20 0.49
TSHR P16473 3/20 0.49
HSP90AA1 P07900 2/20 0.49
BLM P54132 2/20 0.49
NR1H4 Q96RI1 2/20 0.49
CYP2C9 P11712 2/20 0.49
HIF1A Q16665 2/20 0.49
GLA P06280 1/20 0.48
PMP22 Q01453 1/20 0.48
CYP2C19 P33261 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2163300 1.00 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL93717 1.00 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL27925466 0.93 LMNA (0.66) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL27768779 0.93 LMNA (0.66) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL27493791 0.92 LMNA (0.64) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL27469410 0.89 LMNA (0.60) LMNASMN1; SMN2MEN1KMT2ACYP1A2
Zinc Ion SCHEMBL7620932 0.87 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL27669980 0.87 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL2507637 0.87 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2
SCHEMBL3899729 0.87 LMNA (0.58) LMNASMN1; SMN2MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120078664-A Hair-fixing and hair-losing-preventing composition and application thereof, and hair-fixing and hair-preventing be temporarily released from one's regular work product 上海中翊日化有限公司 2025-06-03 CN claimed
CN-120053314-A Hair-fixing and hair-losing-preventing composition and application thereof, and hair-fixing and hair-preventing be temporarily released from one's regular work product 上海中翊日化有限公司 2025-05-30 CN claimed
CN-118845516-A Alopecia preventing composition and application thereof 上海中翊日化有限公司 2024-10-29 CN claimed
US-20240324593-A1 OCTENIDINE COMPOSITIONS AND METHODS OF USE THEREOF SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2024-10-03 US claimed
CN-118388631-A Anti-hair loss essence containing recombinant human XVII collagen and preparation method thereof 西安巨子生物基因技术股份有限公司 2024-07-26 CN claimed
EP-4373276-A1 OCTENIDINE COMPOSITIONS AND METHODS OF USE THEREOF Solventum Intellectual Properties Company (US) 2024-05-29 EP claimed
CN-117677295-A Octenidine compositions and methods of use thereof 3M创新有限公司 2024-03-08 CN claimed
WO-2023194470-A1 IMPROVING SEMEN QUALITY THE CEUTICS COMPANY GESMBH (AT) 2023-10-12 WO claimed
EP-4243804-A1 SUBSTANCES FOR TREATMENT OF HYPERURICAEMIA ScandiBio Therapeutics AB (SE) 2023-09-20 EP claimed
EP-3220893-B1 COMPOSITION BASED ON COQ10 ASOLTECH SRL (IT) 2023-06-07 EP claimed
US-20090304620-A1 HAIR TREATMENT PRODUCTS COMPRISING POLYMERS HENKEL AG & CO. KGAA (DE) 2009-12-10 US claimed
WO-2008107197-A2 NUTRIENT COMPOSITIONS PHARES PHARMACEUTICAL RESEARCH N.V. (AN) 2008-09-12 WO claimed
EP-1964555-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTANCES THAT INHIBIT THE REUPTAKE OF NORADRENALINE, DOPAMINE AND SEROTONIN, WHICH ARE COMBINED WITH AN AMINO ACID FOR THE TREATMENT OF OBESITY AND OVERWEIGHT Espinosa Abdala, Leopoldo de Jesús (MX) 2008-09-03 EP claimed
WO-2005123108-A2 ADVANCED VITAMINS AND PROTEIN BASED NUTRITIONAL SUPPLEMENTS FEINSTEIN WILLIAM (US) 2005-12-29 WO claimed
US-20040052926-A1 Dietetic food for breaking down fat APFELBAUM UDO (CH) 2004-03-18 US claimed
US-6528042-B1 Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. These compositions comprise a flavonoid or derivative thereof and a synergist. Synergists include such as GALILEO LABORATORIES, INC. 2003-03-04 US claimed
CN-1248967-A Process for the preparation of stable non-hygroscopic salts of L -carnitine and alkanoyl L -carnitines SIGMA TAU IND FARMACEUTI (IT) 2000-03-29 CN claimed
EP-0497834-A1 CARNITINE SUPPLEMENTED CAT FISH DIET THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1992-08-12 EP claimed
US-5030657-A Fat reduction, ammonia resistance UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1991-07-09 US claimed
WO-1991005554-A1 CARNITINE SUPPLEMENTED CAT FISH DIET UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1991-05-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090304620-A1 HAIR TREATMENT PRODUCTS COMPRISING POLYMERS ASS1, SRM, COL1A1 LMNA 2570/4885SMN1; SMN2 2049/4885MEN1 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.